Yükleniyor... / Loading...
This study examined a cellular immunotherapy called Provenge® (Sipuleucel-T) in patients with metastatic prostate cancer that had progressed despite hormone therapy. Patients whose prostate cancer had progressed on hormone therapy and had spread to lymph nodes or bone could take part. The study was carried out in Phase 3 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+31
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
To qualify for this trial, you must have ALL of the following: * Histologically documented adenocarcinoma of the prostate * Cancer that has progressed while on adequate hormone therapy. This state of the disease is androgen independent prostate cancer (AIPC). * Cancer that has spread outside the prostate (metastatic) to lymph nodes or bone. Please note that if your cancer has spread to organs (e.g., liver, lung, brain), you are not eligible for the study. * The absence of or minimal current cancer-related pain Please note that there are additional eligibility criteria. The study center will determine if you meet all of the criteria. Study personnel will explain the trial in detail and answer any questions you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, study personnel will explain the reasons.